Primary prevention of venous thromboembolism in medical and surgical oncology patients.
Recent data suggest that patients with a malignancy have a seven-fold increased risk for venous thromboembolism (VTE) compared with those without cancer, suggesting that these patients may benefit from thromboprophylaxis. Mechanisms for the prevention of thromboembolism can be divided into two broad categories: mechanical and pharmacological. Although generally used in combination with pharmacotherapy, little evidence exists for the efficacy of mechanical modalities either in the broader population of patients at risk for VTE or for patients with cancer specifically. A recent study using graduated compression stockings (GCS) for thromboprophylaxis showed no support for the use of stockings in acute stroke patients. Established pharmacological modalities, including warfarin, unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and the factor Xa inhibitor fondaparinux, have been shown to reduce risk for VTE in general medical and surgical populations. In medical cancer patients, only limited data are available for the efficacy of thromboprophylaxis. In contrast, considerable evidence indicates that thromboprophylaxis is warranted in patients undergoing cancer surgery. The most recent evidence suggests that catheter-related thrombosis is not prevented by current pharmacological modalities. On 22 May 2009, a group of clinicians based in the United Kingdom (UK) met in London, UK, to evaluate recent data on cancer thrombosis. This article (the second of four) briefly reviews key data on the prevention of VTE in medical and surgical oncology patients, providing context for a brief transcript of the surrounding discussion and a consensus statement, developed by meeting attendees, on the implications of this information for UK clinical practice.
Stanley
A
A
Birmingham Treatment Centre, City Hospital, Dudley Road, Birmingham B18 7QH, UK. andrew.stanley@westmidlands.nhs.uk
Young
A
A
D002405:Catheterization, Central Venous / Q000009:adverse effects; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000601:surgery; D017410:Practice Guidelines as Topic; D054556:Venous Thromboembolism / Q000517:prevention & control*
Thromb Haemost. 2008 Jan;99(1):38-43
18217132
JAMA. 2006 Dec 6;296(21):2558-60
17148721
Thromb Haemost. 1995 Oct;74(4):1055-8
8560413
Lancet. 2007 Sep 15;370(9591):949-56
17869635
BMJ. 2006 Feb 11;332(7537):325-9
16439370
N Engl J Med. 2002 Mar 28;346(13):975-80
11919306
J Clin Oncol. 2006 Mar 1;24(7):1112-8
16505431
N Engl J Med. 1999 Sep 9;341(11):793-800
10477777
JAMA. 2005 Feb 9;293(6):715-22
15701913
Blood. 2002 Sep 15;100(6):2272-3
12229885
J Bone Joint Surg Br. 2009 May;91(5):636-44
19407299
Chest. 2008 Jun;133(6 Suppl):381S-453S
18574271
J Clin Oncol. 2007 Dec 1;25(34):5490-505
17968019
Lancet. 2009 May 16;373(9676):1673-80
19411100
N Engl J Med. 2008 Jun 26;358(26):2776-86
18579812
Chest. 2008 Jun;133(6 Suppl):141S-159S
18574264
Ann Surg. 1988 Aug;208(2):227-40
2456748
Lancet. 1994 Apr 9;343(8902):886-9
7908358
Arch Intern Med. 2000 Mar 27;160(6):809-15
10737280
J Thromb Haemost. 2007 Nov;5(11):2178-85
17764540
J Clin Oncol. 2000 Sep;18(17):3078-83
10963635
Oncologist. 2003;8(4):381-8
12897335
Arch Intern Med. 2006 Feb 27;166(4):458-64
16505267
Blood. 2001 Sep 1;98(5):1614-5
11520815
Oncologist. 2005 Jan;10(1):72-9
15632254
J Thromb Haemost. 2005 Jan;3(1):28-34
15634263
Ann Oncol. 2008 May;19 Suppl 2:ii126-7
18456750
J Clin Oncol. 2006 Jan 20;24(3):431-6
16365178
Am J Med. 2007 Oct;120(10):901.e1-13
17904462
Blood. 2002 Nov 15;100(10):3484-8
12393647
Br J Surg. 2005 Oct;92(10):1212-20
16175516
Lancet. 2009 Jun 6;373(9679):1958-65
19477503
Curr Opin Investig Drugs. 2008 Sep;9(9):1020-33
18729009
Chest. 2004 Sep;126(3 Suppl):311S-337S
15383477
Ann Surg Oncol. 2007 Feb;14(2):929-36
17103259
J Clin Oncol. 2004 May 15;22(10):1944-8
15143088
Lancet. 2009 Feb 14;373(9663):567-74
19217991
Thromb Haemost. 2009 Apr;101(4):780-2
19350128